{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(8)"],"submitter":["Mathieu C"],"journal":["Diabetes, obesity & metabolism"],"pagination":["2023-2028"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6055818"],"abstract":["Glucagon-like peptide-1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose-dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta-cell function (as measured by HOMA2-%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide-treated patients from AWARD-1, AWARD-3 and AWARD-6 clinical studies were categorised based on their homeostatic model assessment of beta-cell function (HOMA2-%B) tertiles. Changes in glycaemic measures in response to treatment with once-weekly dulaglutide were evaluated in each HOMA2-%B tertile. Patients with low HOMA2-%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes (P?<?.001, all) (mean low, middle and high tertiles with dulaglutide 1.5?mg: HOMAB-2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26?weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5?mg (mean; -1.55% vs. -0.98% [-16.94 vs. -10.71?mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; -1.00 vs. -1.18% [-10.93 vs. -12.90?mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C-peptide were observed in the low tertile. Similar increases in HOMA2-%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta-cell function."],"repository":["biostudies-other"],"pmcid":["PMC6055818"],"data_source":["Europe PMC"],"pubmed_authors":["Pavo I","Jia N","Thieu VT","Karanikas CA","Garcia-Perez LE","Botros FT","Mathieu C","Del Prato S","Haupt A"],"additional_accession":[]},"is_claimable":false,"name":"Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.","description":"Glucagon-like peptide-1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose-dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta-cell function (as measured by HOMA2-%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide-treated patients from AWARD-1, AWARD-3 and AWARD-6 clinical studies were categorised based on their homeostatic model assessment of beta-cell function (HOMA2-%B) tertiles. Changes in glycaemic measures in response to treatment with once-weekly dulaglutide were evaluated in each HOMA2-%B tertile. Patients with low HOMA2-%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes (P?<?.001, all) (mean low, middle and high tertiles with dulaglutide 1.5?mg: HOMAB-2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26?weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5?mg (mean; -1.55% vs. -0.98% [-16.94 vs. -10.71?mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; -1.00 vs. -1.18% [-10.93 vs. -12.90?mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C-peptide were observed in the low tertile. Similar increases in HOMA2-%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta-cell function.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Aug","modification":"2019-03-26T23:48:17Z","creation":"2019-03-26T23:48:17Z"},"accession":"S-EPMC6055818","cross_references":{"pubmed":["29603872"],"doi":["10.1111/dom.13313 "]}}